Pulmonx Corporation (FRA:4NI)

Market Cap	42.89M -83.4%
Revenue (ttm)	77.08M +8.0%
Net Income	-45.99M
EPS	-1.13
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	359
Open	1.070
Previous Close	1.100
Day's Range	1.000 - 1.070
52-Week Range	1.000 - 1.920
Beta	n/a
RSI	33.14
Earnings Date	Apr 29, 2026

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with mult...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 1995
• Employees: 296
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4NI

Financial Performance

In 2025, Pulmonx's revenue was $90.50 million, an increase of 8.01% compared to the previous year's $83.79 million. Losses were -$54.00 million, -4.24% less than in 2024.

Financial numbers in USD